African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2198

Full Length Research Paper

Cardioprotective effects of animal grade piperazine citrate on isoproterenol induced myocardial infarction in wistar rats: Biochemical and histopathological evaluation

Ghasi, S. I.
  • Ghasi, S. I.
  • Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria, Enugu, Nigeria.
  • Google Scholar
Umana, I. K.
  • Umana, I. K.
  • Department of Pharmacology and Toxicology, University of Uyo, Uyo, Akwa Ibom State, Nigeria.
  • Google Scholar
Ogbonna, A. O.
  • Ogbonna, A. O.
  • Government House Medical Centre, Enugu, Enugu State, Nigeria,
  • Google Scholar
Nwokike, M. O.
  • Nwokike, M. O.
  • Department of Pharmacology and Therapeutics, College of Health Sciences, Ebonyi State University, Abakaliki, Ebonyi State, Nigeria.
  • Google Scholar
Ufelle, S.
  • Ufelle, S.
  • Department of Medical Laboratory Sciences, Faculty of Health Science and Technology, College of Medicine, University of Nigeria, Nsukka, Nigeria.
  • Google Scholar


  •  Received: 03 March 2020
  •  Accepted: 16 July 2020
  •  Published: 30 September 2020

Abstract

The present study was designed to investigate the cardioprotective effect of animal grade piperazine citrate on isoproterenol-induced myocardial infarction in rats by studying cardiac marker enzymes and histopathological changes of the cardiac muscle. Isoproterenol administration showed significant (P<0.001) increase in the serum levels of cardiac injury markers (creatine kinase-MB and troponin-I), 358.98 ± 7.68 iu/l and 13.16 ± 0.35 ng/ml compared to the normal control group of 291.58 ± 3.56 iu/l and 9.66 ± 0.20 ng/ml respectively. Pretreatment with 15 and 30 mg/kg body weight of piperazine citrate showed a decrease in the troponin-I levels when compared with the isoproterenol group; 13.16 ± 0.35 to 12.39 ± 0.22 ng/ml in the group that received 15 mg/kg piperazine citrate (p = 0.0881) and 13.16 ± 0.35 to 11.79 ± 0.30 ng/ml (p = 0.0132) in case of the group pretreated with 30 mg/kg piperazine citrate. With regards to CK-MB, the treated groups with piperazine citrate 15 and 30 mg/kg body weight showed a reduction in the values, 340.76 ± 5.10 (p = 0.0763) and 344.17 ± 8.24 iu/l (p = 0.2178) respectively, compared to the isoproterenol group value of 358.98 ± 7.68 iu/l. Histopathological investigation showed that there was no significant architectural changes in the normal control group that received only normal saline. Structural aberrations caused by isoproterenol were also significantly reduced in the piperazine citrate treated groups. Therefore, the results of the present study suggest that low dose piperazine citrate has a significant effect on the protection of the heart.

Key words: Piperazine citrate, myocardial infarction, histopathology, Wistar rat.